Why the study?
Device thrombosis is a serious complication after transcatheter structural cardiac interventions, requiring an update to current knowledge on prevention and management.
This review highlights the necessity of tailored antithrombotic or antiplatelet therapy and echocardiographic follow-up to prevent and manage device-related thrombosis following structural heart interventions.
Should not yet change practice beyond tailored therapy and surveillance; leaves open RCTs to define optimal antithrombotic strategies.
Transcatheter interventions enable safe and efficient treatment of various structural heart diseases. However, therapy does not finished with the end of the procedure. Device thrombosis is a possible serious complication. Therefore, careful patient management should include optimal antiplatelet or antithrombotic medication to enhance safe and complete endothelial coverage of the implanted device. In case of thrombus formation careful diagnostic evaluation and prompt treatment is crucial. This paper provides an update to current knowledge and understanding of prevention and management of device related thrombosis.
No takes yet. Share an insight, caveat, or question.
Olasińska‐Wiśniewska et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: